Lara Chaaban

Lara Chaaban

Auto-generated profile, based on publicly available information

Lara Chaaban

Division of Gastroenterology and Hepatology, Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, MD

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2023 in Gastro Hep Advances
Verified
Journal Article
Open access
JAJulia Angkeow
Julia Angkeow
ARAlissa Rothman
Alissa Rothman
LCLara Chaaban
Lara Chaaban
NPNicole Paul
Nicole Paul
JMJoanna Melia
Joanna Melia
Approximately 1 in 4 patients with ulcerative colitis experiences a severe exacerbation of disease requiring hospitalization, termed acute severe ulcerative colitis (ASUC). These episodes pose a major burden on patients with ulcerative colitis and early prediction of their outcomes based on clinical data is crucial to optimize therapy. A systematic review was performed using Embase and Medline for articles between 2000 and 2023. Studies obtained from the databases were uploaded on Covidence for screening by 2 independent reviewers. Quality appraisal for each study was done using the Critical Appraisals Skills Program depending on study design. A total of 48 eligible studies were included in the review. The key predictors of ASUC identified in this review included clinical, endoscopic, and radiographic biomarkers, which were summarized. The main outcomes assessed in the studies were intravenous corticosteroid failure, need for rescue therapy, and need for colectomy. Score-based predictions and some novel markers were also included in the results. Utilization of evidence-based predictors of outcome in ASUC could serve as a powerful tool in customizing therapeutic measures and a step forward toward personalized patient care. Despite promising candidates, there remains a significant opportunity to identify and test additional clinical and laboratory-based predictors, especially early in the hospitalization and as the clinical practice and medical therapies evolve.

9 October 2024 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
PDF file
LCLara Chaaban
Lara Chaaban
BCBenjamin Cohen
Benjamin Cohen
RCRaymond K Cross
Raymond K Cross
MKMaia Kayal
Maia Kayal
MLMillie Long
Millie Long
JMJoanna Melia
Joanna Melia
Background and Aims: Acute severe ulcerative colitis (UC) (ASUC) requiring hospitalization affects up to 1 in 4 patients with UC. There is a paucity of prospective and multicenter clinical cohorts to study treatment trends and predictors of disease outcomes. Here, we conduct a US-based multicenter prospective clinical cohort of ASUC to study predictors of the need for medical rescue therapy and colectomy. Methods: A total of 94 patients hospitalized for ASUC were included across 5 academic centers from December 2018 to December 2021. Demographic, clinical, and laboratory data were collected throughout the hospitalization. Patients were followed up to 1-year post-hospitalization to identify predictors of the need for rescue therapy and colectomy. Results: A total of 21 (22.3%) patients required colectomy within 1 year of admission with 11 (12%) requiring colectomy during the index admission. On multivariate analyses, a BMI < 21.5 kg/m2 (OR = 6.16, P = .02), a simple clinical colitis activity index (SCCAI) greater than 8 (OR = 14.44, P = .01) and an albumin level at admission lower than 2.4 g/dL (OR = 10.61, P = .04) were significant predictors of inpatient colectomy after adjusting for sex, age, and duration of disease. Conclusions: In a prospective, multicenter cohort of patients hospitalized with ASUC, BMI, SCCAI, and albumin at admission were important determinants of colectomy risk during the index hospitalization and within 1 year of admission. Colectomy rates remain high—22.3% in this cohort across 5 academic, tertiary care centers—underscoring the need to identify the highest-risk patients, establish novel treatment and care paradigms, and examine opportunities to standardize care.

16 December 2025 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
ASAndrew Suchan
Andrew Suchan
LCLara Chaaban
Lara Chaaban
LKLynn Kobeissi
Lynn Kobeissi
BHBashar A Hassan
Bashar A Hassan
FLFan Liang
Fan Liang
JMJoanna M Melia
Joanna M Melia
Background: Transgender and nonbinary (TGNB) individuals comprise 0.5% to 0.6% of the U.S. population and face significant healthcare disparities, yet little is known about inflammatory bowel disease (IBD) in this group. We aimed to characterize IBD prevalence, comorbidities, healthcare utilization, and the impact of hormone replacement therapy (HRT) in TGNB individuals. Methods: Using TriNetX, we analyzed (1) IBD prevalence among TGNB adults, (2) comparisons of IBD patients who are and who are not TGNB, and (3) comparisons of TGNB IBD patients with and without HRT. Outcomes included demographics, comorbidities, laboratory markers, healthcare encounters, IBD treatment, and cardiovascular and thrombotic events. Results: Of 111 227 TGNB patients, prevalence of Crohn’s disease and ulcerative colitis was 0.508% and 0.448%, respectively, increasing with age. TGNB patients were younger (32.5 years of age vs 46.9 years of age; P < .001), exhibited higher rates of gastrointestinal and psychiatric comorbidities, and had more outpatient, emergency, and hospital visits, yet they underwent fewer endoscopies (25.7% vs 30.7% risk; P = .011) and were less likely to receive targeted IBD therapy than cisgender patients. Patients with HRT had more outpatient encounters (66.7% vs 58.2%; P = .010) and were more likely to use therapies like mesalamine (12.4% vs 7.6%; P = .021) than those without HRT. There were no significant differences in laboratory markers or thrombotic or cardiovascular events in these analyses. Conclusions: TGNB IBD patients experience greater gastrointestinal and psychiatric comorbidities and receive fewer interventions overall despite greater healthcare contact. HRT was not associated with worsening disease or complications. These findings highlight critical disparities and the need for further research in this population.

2 February 2026 in Gastro Hep Advances
Verified
Journal Article
Open access
ARAlissa Rothman
Alissa Rothman
LCLara Chaaban
Lara Chaaban
JMJoanna Melia
Joanna Melia
Sex-based differences in immune-mediated diseases are becoming more widely recognized, but there is very limited research exploring sex-based differences in ulcerative colitis (UC), particularly more severe forms of UC. Some recent studies have suggested lower colectomy rates in female patients with UC. The objective of this study is to assess the association between sex and outcomes of patients with UC, particularly those with more severe forms of the disease requiring hospitalization. A propensity score matched retrospective cohort study was performed using TriNetX, a multi-institutional database, to compare risk of colectomy, hospitalization, and mortality between male and female patients with UC, including subgroup analyses of those who had been hospitalized, had received intravenous steroids within 2 weeks of hospitalization or had received infliximab within 1 month of hospitalization. Males had a statistically significant increased risk of colectomy (odds ratio (OR) 1.50, 95% confidence interval (CI) 1.40–1.61; OR 1.47, 95% CI 1.38–1.57), hospitalization (OR 1.04, 95% CI 1.02–1.06; OR 1.02, 95% CI 1.00–1.04), and mortality (OR 1.28, 95% CI 1.21–1.34; OR 1.32, 95% CI 1.28–1.37) at 1 year and at 5 years after diagnosis. Similar results were found when focusing on hospitalized UC patients and males receiving intravenous steroids within 2 weeks of hospitalization. For patients receiving infliximab within 1 month of hospitalization only colectomy rates were significantly different between males and females at the 1-year timepoint. Male patients with UC are at higher risk for colectomy, hospitalization, and mortality than females with UC.